TD Cowen analysts reaffirmed their Buy rating and maintained a $130 price target on Abbott Labs (NYSE:ABT) stock. The analysts expressed confidence that Abbott's upcoming third-quarter results will likely meet or exceed Wall Street expectations, positioning the company to achieve its full-year guidance.

The analysts pointed to several new product launches, including the recent introduction of Abbott's Lingo CGM sensor in the U.S., as key growth drivers. These developments, combined with the company's core business strength, bolster optimism for Abbott’s outlook, despite potential risks from the ongoing NEC litigation.